Cargando…
Disease Reactivation after Fingolimod Discontinuation in Pregnant Multiple Sclerosis Patients
Recent studies estimated an incidence of 4–25% of disease rebound after withdrawal of fingolimod (FTY) for any reason, but specific data on disease reactivation after FTY withdrawal due to pregnancy are limited. The aim of the study was to evaluate the frequency and predictors of disease reactivatio...
Autores principales: | Bianco, Assunta, Lucchini, Matteo, Totaro, Rocco, Fantozzi, Roberta, De Luca, Giovanna, Di Lemme, Sonia, Presicce, Giorgia, Evangelista, Luana, Di Tommaso, Valeria, Pastorino, Roberta, De Fino, Chiara, De Arcangelis, Valeria, Centonze, Diego, Mirabella, Massimiliano |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8803993/ https://www.ncbi.nlm.nih.gov/pubmed/34494237 http://dx.doi.org/10.1007/s13311-021-01106-6 |
Ejemplares similares
-
The Expanding Role of the Infectious Disease Expert in the Context of the MS Centre
por: Lucchini, Matteo, et al.
Publicado: (2022) -
CSF CXCL13 and Chitinase 3-like-1 Levels Predict Disease Course in Relapsing Multiple Sclerosis
por: Lucchini, Matteo, et al.
Publicado: (2022) -
Fingolimod Treatment in Relapsing-Remitting Multiple Sclerosis Patients: A Prospective Observational Multicenter Postmarketing Study
por: Totaro, Rocco, et al.
Publicado: (2015) -
Serum-Circulating microRNAs in Sporadic Inclusion Body Myositis
por: Lucchini, Matteo, et al.
Publicado: (2023) -
Is serological response to SARS-CoV-2 preserved in MS patients on ocrelizumab treatment? A case report
por: Lucchini, Matteo, et al.
Publicado: (2020)